Literature DB >> 2555743

Chronic opiate receptor activation in vivo alters the level of G-protein subunits in guinea-pig myenteric plexus.

J Lang1, R Schulz.   

Abstract

Studies with the longitudinal muscle-myenteric plexus preparation of the guinea-pig ileum were undertaken to investigate the relationship between guanine nucleotide-binding proteins (G-proteins) and chronic opioid receptor activation in vivo. Treatment with the narcotic agonist fentanyl, at doses which render the preparation tolerant and dependent, led to an increase of pertussis toxin-catalysed incorporation of ADP-ribose in a protein of approximately 40,000 mol. wt. Quantitative immunoblotting, using site-directed antisera, demonstrated an upregulation of G alpha i/G alpha o and, to an even greater degree, of G beta. However, the level of G alpha s was decreased by the same treatment. All alterations observed were abolished by the concomitant presence of the antagonist naloxone. The implications of this differential regulation of G-protein subunits for opiate-induced tolerance and dependence are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555743     DOI: 10.1016/0306-4522(89)90097-3

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  3 in total

1.  Alterations in the expression of G-proteins and regulation of adenylate cyclase in human neuroblastoma SH-SY5Y cells chronically exposed to low-efficacy mu-opioids.

Authors:  H Ammer; R Schulz
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

2.  Changes of the level of G protein alpha-subunit mRNA by tolerance to and withdrawal from butorphanol.

Authors:  Dong Sup Kim; Hwa Kyung Lim; Soyong Jang; Seikwan Oh
Journal:  Neurochem Res       Date:  2003-12       Impact factor: 3.996

Review 3.  Opioid tolerance and the emergence of new opioid receptor-coupled signaling.

Authors:  A R Gintzler; S Chakrabarti
Journal:  Mol Neurobiol       Date:  2000 Feb-Apr       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.